Avalon GloboCare Corp.

Avalon GloboCare Corp. operates commercial real estate properties in the US and China, offering medical consulting services, research studies, and management services in immunotherapy and second opinion/referral services. Its leading candidates include AVA-001, an anti-CD19 CAR-T, and AVA-011, a pre-clinical stage RNA-based FASH-CARTM cell therapy platform. The company also develops avalon clinical-grade tissue-specific exosome (ACTEX) and therapeutic and diagnostic targets utilizing QTY-code protein design technology with MIT. Additionally, it has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna to develop an S-layer vaccine against SARS-CoV-2. Avalon GloboCare Corp. also promotes standardization related to the exosome industry.

Products

• Medical consulting services

• Immunotherapy candidates

• RNA-based cell therapy platform

• Tissue-specific exosome development

• S-layer vaccine development